Abstract. Oral squamous cell carcinoma (OSCC) is a type of head and neck malignancy with a high mortality rate. Oral submucous fibrosis (OSF) is the pre-cancerous lesion of OSCC, whose molecular mechanisms in OSCC tumorigenesis remain largely unclear. Activation of the Wnt/β-catenin signaling pathway plays an important role in oral mucous carcinogenesis, although rare mutations of Wnt signaling molecules are found in OSCC, suggesting an epigenetic mechanism mediating aberrant Wnt/β-catenin signaling in OSCC. Wnt inhibitory factor-1 (WIF1) is an Wnt antagonist, and its downregulation and methylation have been reported in a number of malignancies. However, the expression and methylation of WIF1 in the development of OSF have yet to be reported. In the present study, we investigated the WIF1 expression level by immunohistochemical staining and semi-quantitative RT-PCR in normal oral, OSF and OSCC tissues, as well as the methylation status by methylation-specific PCR and bisulfite genomic sequencing. The results showed that WIF1 was readily expressed in normal oral mucous tissues, but decreased gradually in OSF early, moderately advanced and advanced tissues, and was less expressed in OSCC tissues. Moreover, WIF1 was able to translocate from the nuclear to cytoplasm in OSF and OSCC tissues. Furthermore, WIF1 was frequently methylated in OSCC cases with betel quid chewing habit, but not in normal oral mucous and different stages of OSF tissues, suggesting WIF1 methylation is tumor-specific in the development of OSF. Thus, the results demonstrated that WIF1 is frequently downregulated or silenced by promoter methylation in the carcinogenesis of OSF, which serves as a potential epigenetic biomarker for the early detection of OSCC.
Introduction
Oral squamous cell carcinoma (OSCC) is a common type of cancer of the head and neck region, with a high mortality rate and rising incidence (1, 2) . Oral carcinogenesis is a complex multi-step process, undergoing sequential histopathological stages including hyperplasia, oral epithelial dysplasia and final malignant phenotypes (3, 4) . Despite significant advances in the diagnosis and treatment of OSCC in recent years, 5-year survival rate remains low due to late-stage diagnosis.
Oral submucous fibrosis (OSF), as a pre-cancerous condition (5) , is a chronic and potentially malignant disorder, first described in the early 1950s by Pindborg and Sirsat (6) . OSF is predominantly prevalent in Indian, mainland China (such as Hunan and Hainan), Taiwan, Bangladesh and Pakistan (7) . It is characterized by submucosal fibrosis initially occurring in the oral cavity and then progressively infringing the pharynx and upper esophagus (8) . The malignant transformation rate of OSF has been reported in the range of 7-30% based on the different population (9) . The etiology of OSF is multifactorial and remains vague. Chewing of betel quid containing areca nut is the strongest risk factor of OSF, and other factors include tobacco use, alcohol drinking, as well as genetic and immunologic predisposition (10) (11) (12) . Thus, elucidating the molecular events of OSF malignant progression may be useful in identifying potential biomarkers for the early diagnosis and prevention of OSCC.
Epigenetic modifications including the promoter CpG methylation and histone modification have been recognized as being crucial events in cancer development, such as genetic Expression and promoter methylation of Wnt inhibitory factor-1 in the development of oral submucous fibrosis alterations (13, 14) . Aberrant promoter methylation leads to the transcriptional silencing of tumor-suppressor genes (TSGs), involved in cell malignant transformation and tumorigenesis. Detection of promoter CpG methylation in human DNA isolated from primary tumor tissues and bodily fluids has become a promising approach for non-invasive screening and early diagnosis of cancer (15) . Several TSgs have been identified methylated in OSCC (16) (17) (18) (19) , such as p16, p14arf, E-cadherin, O-6-methylgua-nine-DNA methyltransferase (MGMT), deathassociated protein kinase (DAPK), runt-related transcription factor 3 (RUNX3), as well as certain Wnt antagonists. The Wnt/β-catenin signaling pathway plays an important role in human malignancies including OSCC (20, 21) . Wnt inhibitory factor-1 (WIF1) as a secreted WnT antagonist inhibits Wnt/β-catenin signaling by directly binding to Wnt proteins (22) . However, few studies have focused on the epigenetic disruption of WIF1 in OSF progression. In the present study, we investigated the expression level and methylation status of WIF1, a key antagonist in WnT signaling, in the carcinogenesis of OSF. Immunohistochemistry. Immunohistochemical staining was performed on 4-µm serial sections from formalin-fixed paraffin-embedded specimens. Following deparaffinization and hydration, the slides were treated with endogenous peroxidase in 3% H 2 O 2 for 20 min, after which the sections were blocked for 30 min at 37˚C with 1.5% blocking serum in phosphate-buffered saline (PBS) prior to reacting with WIF1 antibody (1:100 dilution, AP2723a; Abgent, San Diego, CA, uSA) at 4˚C in a moist chamber overnight. negative control slides were duplicate sections in the absence of primary antibodies. To evaluate WIF1 expression, a scoring method was used. A mean percentage of positive tumor cells was determined by the examination of 500 cells in at least 5 areas at x400 magnification. The cells were assigned to 1 of the 5 following categories according to percentage of positive cells (PP): 0) <5%, 1) 5-24%, 2) 25-49%, 3) 50-75%, and 4) >75%. The intensity of the WIF1 staining (SI) then was scored as follows: 0) no, -; 1) weak, +; 2) moderate, ++; and 3) intense, +++. The final immunoreactive score (IRS=SI + PP) was as follows: -) 0, 1; +) 2, 3; ++) 4, 5; and +++) 6, 7. The stained tissues were scored blindly with regard to clinical patient data. Statistical analyses were performed with the SPSS 17.0 software. Statistical significance was evaluated by the Chi-square test (χ 2 ).
Materials and methods

Tissue
Reverse transcription-polymerase chain reaction. Total RNAs were extracted using TRIzol reagent (Invitrogen Life Technologies, karlsruhe, Germany) according to the manufacturer's instructions. Reverse transcription polymerase chain reaction (RT-PCR) was performed with the use of a kit from Promega (Madison, WI, uSA). Quantitative PCR was performed to detect WIF1 expression, according to the manufacturer's instructions (HT7500 system; Applied Biosystems, Foster City, CA, uSA). Primers for the amplification of WIF1 mRNA sequences (accession no. u75285) were synthesized as previously described (24, 25) . The 257-bp mRNA of WIF1 was amplified by PCR using the primers: forward, 5'-TATggA TCGATGCTCACCAG and reverse, 5'-CAGAGGGACATT GACGGTTG. GAPDH was used as an internal control. Primers used for GAPDH were: forward, 5'-ATCTCTGCC CCCTCTGCTGA-3' and the reverse, 5'-GATGACCTTGCC CACAgCCT-3'. PCR amplification was performed as follows: denaturation at 94˚C for 30 sec, annealing at 55˚C for 30 sec, and extension at 72˚C for 30 sec in 32 cycles. The PCR products were visualized on 2% agarose gels under ultraviolet transillumination.
Methylation-specific PCR and bisulfite genomic sequencing.
Bisulfite modification of DNA, methylation-specific PCR (MSP) and bisulfite genomic sequencing (BGS) were performed as previously described (24) (25) (26) (27) . Bisulfite-treated DnA was amplified with the methylation-specific primer set WIF1-m3: 5'-TGTCGTTTTTATTTTCGTTCGC, WIF1-m4: 5'-CGTTTAAACGACTAAACGCG or the unmethylation specific primer set WIF1-u3: 5'-TTTTTGTTGTTTTTATTT TTGTTTGT, WIF1-u4: 5'-TCCCATTTAAACAACTAAAC ACA. MSP was performed using AmpliTaq Gold (methylation-specific primer: annealing temperature 60˚C, 40 cycles, unmethylation-specific primer: annealing temperature 58˚C, 40 cycles). For BgS, bisulfite-treated DnA was amplified using primers BGS1: 5'-GTTTTAGGGGTTTTTGAGTGTT and BGS2: 5'-CAACTCCCTCAACCAAAACTA. The 463-bp PCR products were cloned into the pCR4-TOPO vector (Invitrogen, Carlsbad, CA, uSA), with 8-10 colonies being randomly selected and sequenced. (Fig. 1) .
Results
Downregulation
The average values of WIF1 expression varied in different tissue samples, including mean score of 5.37 in normal oral mucous tissues, 3.29 in OSF tissues, and 1.27 in OSCC tissues (Table I ). WIF1 expression was gradually reduced in normal Table I . WIF1 expression in the carcinogenesis of oral submucous fibrosis (OSF).
WIF1
Mean (Fig. 2C) . We also found that WIF1 was barely detected in OSCC tissues, compared with their paired adjacent normal tissues (Fig. 2D) . RT-qPCR also confirmed that a reduced expression of WIF1 mRNA in OSCC tissues, compared to the adjacent normal or OSF tissues (Fig. 2e) . Therefore, WIF1 mRNA expression levels are decreased in the carcinogenesis of OSF.
Promoter methylation of WIF1 in the carcinogenesis of OSF.
We investigated the possible regulatory mechanism of WIF1 reduction in the carcinogenesis of OSF. As promoter methylation mediates transcriptional repression of TSGs, we initially examined the presence of CpG island (CGI) in the WIF1 promoter and exon 1 by bioinformatics analysis. The region spanning the WIF1 promoter and exon 1 fulfilled the criteria of a Cpg island (gardiner-garden and Frommer, 1987): gC content, 58.8%; observed/expected Cpg ratio, 0.73; and a total of 46 Cpg sites in a 2026-bp region (Fig. 3) , thus as a typical CGI. We detected the promoter methylation of WIF1 in normal oral mucous and OSF tissues, OSCC and their paired adjacent OSF or normal tissues. We found that WIF1 methylation was not detected in 10 normal oral tissues, 10 OSF tissues from early stage, moderately advanced stage and advanced stage ( Fig. 4A and B) . We also found that WIF1 was frequently methylated in 16 of 20 (80%) OSCC tumor tissues, but not any in their paired adjacent normal and OSF tissues (Fig. 4C-e) . Table II . Correlation between WIF1 expression and clinicopathological characteristics in OSCC cases These results suggested that the promoter methylation of WIF1 is a tumor-specific event in the carcinogenesis of OSF.
Bisulfite genomic sequencing of the WIF1 promoter in OSF and OSCC tumor tissues. To confirm MSP data, high resolution methylation analysis on every CpG site in the WIF1 promoter was carried out by using bisulfite genomic sequencing (BgS). We found that no or very few methylated CpG sites were detected in representative normal oral mucous tissues, and OSF early stage and moderately advanced stage tissues, while methylated alleles were detected in OSCC tissues, but not in their paired normal and OSF tissues. The results confirmed the MSP analysis (Fig. 5 ).
Discussion
Emerging evidence has shown that the epigenetic silencing of cancer genes via promoter CpG methylation plays an important role in OSCC pathogenesis. Several genes have been identified to be aberrantly methylated in OSCC, some of which exhibited a potential as biomarkers, for example, E-cadherin promoter methylation is associated with the poor survival in advanced OSCC (16) , thus is an ideal epigenetic biomarker for OSCC. Thus, identifying more methylated genes may be useful to develop epigenetic biomarker for the early detection of OSCC. Wnt signaling pathways include the canonical Wnt, the non-canonical planar cell polarity and the non-canonical Wnt/calcium pathways (28) . The canonical Wnt pathway, also known as Wnt/β-catenin pathway, accumulates cytoplasmic β-catenin in and eventual translocates into the nucleus, thus acting as a transcriptional coactivator to activate multiple oncogenic genes, leading to tumorigenesis (29) . The Wnt/β-catenin pathway is deregulated in various common human cancers (30) . Frequent mutations of the signaling molecules in the Wnt/β-catenin pathway have been identified in human cancers, including colon, hepatocellular, breast and prostate carcinomas as well as glioblastoma. However, infrequent mutations of APC, Axin1 and β-catenin genes were reported in OSCC (31) , indicating that mechanisms such as epigenetic modulation mediate inactivation of the Wnt/β-catenin pathway in OSCC.
WIF1, a secreted Wnt inhibitor, is downregulated and methy lated in various carcinomas including hepatocellular (32) , nasopharyngeal (24, 33) , esophageal (5), prostate (34), breast (25) , lung (35) and gastrointestinal (36) malignancies, and promotes tumor development and progression by activating β-catenin. Notably, WIF1 silencing may be an early event in tumorigenesis. Although OSF is the precancerous lesion of OSCC, its molecular mechanisms remain to be elucidated. In the present study, we found that WIF1 either at the protein or mRNA level is highly expressed in normal oral mucous tissues, and is gradually decreased in the different stages of OSF and OSCC tissues. Additionally, WIF1 is frequently methylated in OSCC tissues, but not in normal oral mucous tissues, and their paired adjacent normal or OSF tissues. We also detected WIF1 methylation in a panel of OSCC patient tissues with betel quid chewing habit, and observed WIF1 methylation. These results are consistent with those of other studies on WIF1 methylation in OSCC in Western populations (18) . WIF1 methylation was also reported to be correlated with shorter survival in oral cancer patients (37) . Thus, it may become a tumor marker for the early detection of OSCC. Large-scale studies focusing on OSF and OSCC samples should be conducted to confirm the potential value of WIF1 methylation as an epigenetic biomarker in OSCC in the Chinese population.
In summary, we provide evidence that WIF1 is frequently methylated in OSCC in a Chinese population, but not in normal oral mucous and OSF tissues, which is associated with its reduced expression. The present study reveals a novel epigenetic event in the carcinogenesis of OSF, which shed light on the development of a valuable epigenetic biomarker that may be useful for the early detection of OSCC.
